Suppr超能文献

不适合行经导管二尖瓣置换术患者的管理策略和预后。

Management strategies and prognosis of patients ineligible for transcatheter mitral valve replacement.

机构信息

The Christ Hospital Heart and Vascular Institute and Lindner Center for Research and Education, Cincinnati, OH, United States of America.

Lindner Center for Research and Education, Cincinnati, OH, United States of America.

出版信息

Cardiovasc Revasc Med. 2024 Jul;64:1-4. doi: 10.1016/j.carrev.2024.02.002. Epub 2024 Feb 10.

Abstract

BACKGROUND

Transcatheter mitral valve replacement (TMVR) faces anatomical challenges, currently limiting widespread adoption.

OBJECTIVES

To describe the natural history and prognosis of patients ineligible for various TMVR devices.

METHODS

During a 4-year period (2019-2023) 3 TMVR devices (SAPIEN M3, Intrepid and Alta Valve) became available at a single institution (The Christ Hospital, Cincinnati, OH) in the setting of pivotal clinical trials or early feasibility study. Consenting patients who were deemed ineligible ≥1 of these trials were prospectively studied to capture anatomical reasons for ineligibility, cross-over to alternative mitral valve therapies (surgery or high-risk mitral transcatheter edge to edge repair [M-TEER]), and clinical events.

RESULTS

A total of 61 patients (out of 71 consenting patients or 85.9 %) were deemed ineligible for TMVR during the study period. The mean age was 79.2 ± 8.8 years, 65.6 % were female, with elevated surgical risk (median STS 4.3, IQR: 2.7-7.3). The 2 most common anatomical reasons for ineligibility were increased risk of left ventricular outflow tract obstruction (LVOTO) (n = 24, 39.3 %) and annular size (n = 29, 47.5 %). During follow-up (median 277 [162-555] days) there were 7 deaths (11.5 %) and 12 (19.7 %) hospitalizations for heart failure. Management strategies included high-risk M-TEER in 11 patients (1 death [9.0 %], 0 HF hospitalizations [0 %]), surgery in 9 patients (0 deaths, 1 HF hospitalizations [11.1 %]), and medical management in 41 patients (6 deaths [14.6 %], 11 HF hospitalizations [26.8 %]) (p = 0.715 for mortality and p = 0.093 for HF hospitalizations). Residual MR ≥ moderate was 0 %, 50 %, and 100 % for surgery, M-TEER and medical treatment, respectively (p < 0.001).

CONCLUSIONS

One third of patients deemed ineligible for TMVR are candidates for high-risk M-TEER or surgery with acceptable morbidity and mortality. Our results have practical implications for patient management.

摘要

背景

经导管二尖瓣置换术(TMVR)面临解剖学挑战,目前限制了其广泛应用。

目的

描述不符合各种 TMVR 装置标准的患者的自然病史和预后。

方法

在四年期间(2019-2023 年),在一项单中心(辛辛那提基督医院,俄亥俄州)进行的关键临床试验或早期可行性研究中,有 3 种 TMVR 装置(SAPIEN M3、Intrepid 和 Alta Valve)可用。符合条件但被认为不符合≥1 项试验标准的患者被前瞻性研究,以确定其不符合标准的解剖学原因、是否转为替代二尖瓣瓣叶修复(手术或高危二尖瓣经导管缘对缘修复术[M-TEER])以及临床事件。

结果

在研究期间,共有 61 名(71 名同意患者中的 61 名或 85.9%)患者被认为不符合 TMVR 标准。平均年龄为 79.2±8.8 岁,65.6%为女性,手术风险较高(中位 STS 4.3,IQR:2.7-7.3)。最常见的 2 种不符合标准的解剖学原因是左心室流出道梗阻(LVOTO)风险增加(n=24,39.3%)和瓣环大小(n=29,47.5%)。在随访期间(中位 277[162-555]天),有 7 例死亡(11.5%)和 12 例(19.7%)因心力衰竭住院。管理策略包括高危 M-TEER 治疗 11 例(1 例死亡[9.0%],0 例心力衰竭住院[0%])、手术治疗 9 例(0 例死亡,1 例心力衰竭住院[11.1%])和药物治疗 41 例(6 例死亡[14.6%],11 例心力衰竭住院[26.8%])(p=0.715 用于死亡率,p=0.093 用于心力衰竭住院)。手术、M-TEER 和药物治疗后残余 MR≥中度的比例分别为 0%、50%和 100%(p<0.001)。

结论

三分之一被认为不符合 TMVR 标准的患者是高危 M-TEER 或手术的候选者,其发病率和死亡率可接受。我们的研究结果对患者管理具有实际意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验